Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.

The dynamic methylation of histone lysyl residues plays an important role in biology by regulating transcription, maintaining genomic integrity, and by contributing to epigenetic effects. Here we describe a variety of inhibitor scaffolds that inhibit the human 2-oxoglutarate-dependent JMJD2 subfamily of histone demethylases. Combined with structural data, these chemical starting points will be useful to generate small-molecule probes to analyze the physiological roles of these enzymes in epigenetic signaling.

[1]  R. Sormunen,et al.  Characterization of Recombinant Human Prolyl 3-Hydroxylase Isoenzyme 2, an Enzyme Modifying the Basement Membrane Collagen IV* , 2008, Journal of Biological Chemistry.

[2]  R. Janknecht,et al.  Succinate inhibition of α-ketoglutarate-dependent enzymes in a yeast model of paraganglioma , 2007 .

[3]  Patricia A. Ortiz-Tello,et al.  Specificity and mechanism of JMJD2A, a trimethyllysine-specific histone demethylase , 2007, Nature Structural &Molecular Biology.

[4]  V. Richon,et al.  Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[5]  James E. Bray,et al.  Crystal structures of histone demethylase JMJD2A reveal basis for substrate specificity , 2007, Nature.

[6]  Yi Zhang,et al.  Regulation of histone methylation by demethylimination and demethylation , 2007, Nature Reviews Molecular Cell Biology.

[7]  N. Oldham,et al.  Structural and Mechanistic Studies on the Inhibition of the Hypoxia-inducible Transcription Factor Hydroxylases by Tricarboxylic Acid Cycle Intermediates* , 2007, Journal of Biological Chemistry.

[8]  Ronald Breslow,et al.  Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug , 2007, Nature Biotechnology.

[9]  Min Gyu Lee,et al.  Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. , 2006, Chemistry & biology.

[10]  J R Griffiths,et al.  Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. , 2005, Human molecular genetics.

[11]  C. Schofield,et al.  Selective inhibition of factor inhibiting hypoxia-inducible factor. , 2005, Journal of the American Chemical Society.

[12]  David G. Watson,et al.  Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.

[13]  M. Katoh,et al.  Identification and characterization of JMJD2 family genes in silico. , 2004, International journal of oncology.

[14]  K. Kivirikko,et al.  Characterization of the Human Prolyl 4-Hydroxylases That Modify the Hypoxia-inducible Factor* , 2003, Journal of Biological Chemistry.

[15]  Mircea Ivan,et al.  Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  V. Günzler,et al.  Inhibition of prolyl hydroxylation and procollagen processing in chick-embryo calvaria by a derivative of pyridine-2,4-dicarboxylate. Characterization of the diethyl ester as a proinhibitor. , 1991, The Biochemical journal.